Breaking Finance News

BTIG disclosed Orthofix (NASDAQ:OFIX), boosting its price target to $52.00 earlier today

Just yesterday Orthofix (NASDAQ:OFIX) traded -0.02% lower at $45.12. Orthofix’s 50-day moving average is $47.51 and its 200-day moving average is $42.89. The last stock price is up 13.47% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 162,214 shares of OFIX traded hands, up from an average trading volume of 103,955

Stating a potential upside of 0.15%, BTIG raised the target price of Orthofix (NASDAQ:OFIX) to $52.00

Previously on 06/14/2017, Ladenburg Thalmann Financial Services released a statement about Orthofix (NASDAQ:OFIX) increased the target price from $0.00 to $53.25. At the time, this indicated a possible upside of 0.18%.

Recent Performance Chart

Orthofix (NASDAQ:OFIX)

Orthofix has 52 week low of $32.51 and a 52 week high of $50.40 with a PE ratio of 113.98 and has a market capitalization of $0.

Brief Synopsis On Orthofix (NASDAQ:OFIX)

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim. The Biologics products include AlloQuent Structural Allografts, Trinity ELITE, Trinity Evolution and VersaShield. The Extremity Fixation products include Fixator, Eight-Plate Guided Growth System and Contours VPS Volar Plating System III. The Spine Fixation products include Hallmark Anterior Cervical Plate System, Ascent LE Posterior Occipital Cervico-Thoracic (POCT) System, Firebird Deformity Correction System, Phoenix Minimally Invasive Spinal Fixation System, Samba-Screw System, LONESTAR Cervical Stand Alone (CSA), SKYHAWK Lateral Interbody Fusion System & Lateral Plate System and CENTURION POCT System.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.